Clinical Trial Update: 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of 17-DMAG in patients with advanced solid tumors or lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Small Intestine Cancer

Drugs mentioned

• 17-DMAG (17-Dimethylaminoethylamino-17-Demethoxygeldanamycin) (17-DMAG)

Snippet

Sponsor: National Institutes of Health Clinical Center (CC) | Conditions: Lymphoma, Small Intestine Cancer | Phase 1 | Status: COMPLETED